23andMe Holding Co.

Good day, ladies and gentlemen, and welcome to the 23andMe's Fiscal Year 2022 Second Quarter Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. If anyone should require assistance during the conference, please press star zero on your touchtone telephone. As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Wade Walk, Vice President of Investor Relations. Sir, you may begin.

Thank you. Before we begin, I encourage everyone to go to investors.23andme.com to find the press release we issued earlier today reporting our financial results for the quarter. A replay of today's webcast will also be available on our website for a limited time within 24 hours after the event. Please note that certain statements made during this call regarding matters that are not historical facts including but not limited to management's outlook or predictions for future periods, are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled forward-looking statements in our press release, which applies to this call. Also, please refer to our SEC filings, which can be found on our website and the SEC's website for discussion of numerous factors that may impact our future performance. We also discuss certain non-GAAP measures Important information on our use of these measures and reconciliation to U.S. GAAP may be found in our earnings release. Joining us on our call today are Anne Wojcicki, our Chief Executive Officer and Co-Founder, and Steve Schuch, our Chief Financial Officer. Kenneth Hillen, our Head of Therapeutics, will also be joining us for Q&A. And now I'd like to turn the call over to Anne.

Thank you, Wade. I'm excited to talk to you today about the recent progress we've made on our mission to help people access, understand, and benefit from the human genome. We announced recently that we completed our acquisition of Lemonade Health. We believe this acquisition gets us closer to helping our customers more fully benefit from the genetic information we provide them. We have heard from our customers that they want to be able to do more with the information provided to them through our health reports, but most physicians are not trained in genetics and don't know how to integrate the information. We believe we now have the opportunity to change that and expand on our mission to help people benefit from their genetics. Our focus will now be on the integration and developing a plan to accomplish our goal to provide consumers with convenient access to personalized, proactive, and genetically-based primary care. We believe that by combining Lemonade Health's telemedicine platform including its online team of medical professionals and its digital pharmacy services. With our consumer business, we are taking an important step in transforming the traditional primary care experience and making personalized healthcare a reality. I look forward to telling you more about this as our plans develop and take shape. We also launched three new health reports in the second quarter for our 23andMe Plus members. 23Me Plus is our premium content subscription service that provides subscribers with new reports and features through the course of their subscription, giving them even deeper insights into their health. With our database of over 11 million genotype customers and billions of health-related data points, we are uniquely positioned to provide our customers with these health insights. The new reports included a gallstone report, a gestational diabetes report, and an HDL cholesterol report. Each report uses machine learning to estimate a person's likelihood of developing a specific condition. With the addition of these new reports, we now have over 20 reports as part of our 23andMe Plus subscription. If you are not a 23andMe Plus subscriber, you can learn more about these reports on our website at blog.23andme.com. We are also pleased with the progress of our therapeutics pipeline. Our partner, GSK, expects to report clinical data from the CD96 in 2022. In addition, we expect to start a clinical trial with our wholly owned P006 program by the end of fiscal year 2022. Finally, I'm pleased to welcome a new 23andMe board member. As you may have seen from our press release yesterday, Dr. Sandra Hernandez has joined our board. Sandra is the President and CEO of the California Healthcare Foundation, an independent nonprofit philanthropy dedicated to improving California's healthcare system so that all Californians, especially those with low incomes, can get the care they need. I believe Sandra's perspective and guidance will be a great asset to us as we roll out a new digital primary care experience that delivers personalized preventative care to individuals in an affordable, and accessible way. And with that, I'll turn the call over to Steve to review our financial results for the quarter.